Group items matching

in title, tags, annotations or url

Eli Lilly's weight-loss medicine Mounjaro, also known as tirzepatide, will be available in the UK within weeks as a four-dose pre-filled injection pen. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the drug to treat adults with type 2 diabetes and for weight management in obese patients. Branded as Mounjaro KwikPen, the injection is to be used together with a reduced-calorie diet and increased physical activity, the regulator said. "The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people's health, is clear. "This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month's treatment, of one dose per week," said Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access.

Generic for Xenical (Orlistat) is a lipase inhibitor used to promote weight loss in obese people who have a body mass index (BMI) of 30kg/m² or more. Orlistat is also prescribed to treat obesity in overweight people who may have elevated blood cholesterol, high blood pressure, heart disease, and diabetes.

In this fast paced world human beings are living a luxurious life due to good science most of the works are done by machines, but this lack of physical activity has give way to many diseases and obesity that is considered to be the root cause of many health complications especially it is included into the major risk factors of breast cancer. obesity is the result of unhealthy diet full of fats instead of healthy balanced diet and lack of physical activity so it must be kept at distance by adopting healthy life style.

Here are some tips to finding the best weight supplements for you even if you do not fall under the obese category and just want to shed those extra kilos around your belly. Weight loss through diet supplements and not hardcore exercise or weight training is what every obese and overweight is looking for.

Heavy duty wheelchairs are also often known as "bariatric" wheelchairs. Any home medical products that have high weight capacities, whether they be wheelchairs, commodes, beds or anything else are more commonly referred to as bariatric products in the recent years. Standard or "off the shelf" heavy duty wheelchairs are wheelchairs which will have a weight capacity of somewhere over 350 lbs. Of course, should the need arise custom wheelchairs can be ordered in cases where even heavier weight capacities are required. Features Aluminum footplates are attractive, crack-proof and lightweight Carbon steel frame with TRIPLE coated chrome for an attractive, chip-proof, maintainable finish Comes standard with carry pocket on back rest Composite Mag-style wheels with chrome hand rim are lightweight and maintenance free Padded armrests provide added patient comfort Precision sealed wheel bearings in front and rear ensure long lasting performance and reliability Heavy duty bariatric wheelchairs for the larger user and the obese. Including extra large self propelled wheelchairs, heavy duty transfer wheelchairs and bariatric transport wheelchairs for the larger or obese user.Heavy duty wheelchairs are made with stronger axles, heavier tubing, double cross braces, gusseted frames and reinforced upholstery to be able to handle the weights required. karma km-8520 Item Code:WCI-29 MRP: R 32085 Our Price:R24063 Net Price:R23582( Apply Coupon Code 'MSW2365' Get 2% Discount ) Availability:Not Available Pin Code:Delivery All Over India (Free Shipping) Warranty:1 Year Seat Widths and Depths Seat widths for heavy duty wheelchairs will range from about 20" to about 30" depending on the model chosen. Seat depths for heavy duty wheelchairs will range from about 18" to about 24" depending on the model chosen. Seat Height Seat heights on a heavy duty wheelchair range between 15" and 22" depe

The Weight loss is almost every Obese person's dream in America. According to a 2014 study there were 36% Americans suffer from overweight or Obese according to the Centers for Disease Control and Prevention which, according to a new study it will be almost 3/4 by 2020.

New research shows that lifelong excess weight almost doubles a woman's risk of developing womb cancer. The findings of the study were published in 'BMC Medicine'. The study from the University of Bristol is one of the first to find that for every fiver extra BMI units, a woman's risk of womb (endometrial) cancer is almost doubled (an increase of 88 per cent). This is higher than most previous studies have suggested and reflects lifelong weight status rather than a snapshot in time like most other studies. Five BMI units is the difference between the overweight category and the obese category, or of a 5'5 adult woman being two stones heavier. The international study looked at genetic samples from around 120,000 women from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA of which around 13,000 had womb cancer. This large statistical analysis is one of the first studies of its kind to look at the effect of lifelong greater BMI on womb cancer risk.

Weight loss drug Wegovy has transformed the obesity market and pharmaceutical companies with existing treatments are hoping the resulting demand will boost demand for their older, less effective but cheaper, drugs. A weekly injection of Wegovy, which was launched in the U.S. in June 2021, leads to an average weight loss of around 15%, alongside changes to diet and exercise. Its impact has captured the attention of patients, investors and even celebrities. But supply issues for Wegovy manufacturer Novo Nordisk means the Danish drugmaker has struggled to meet surging U.S. demand, delaying a launch in most of Europe. Insurers and some national governments have also baulked at its cost, while a minority of patients do not respond to it. Vivus and Currax Pharmaceuticals, U.S.-based developers whose treatments have been on the U.S. market for around a decade, hope to benefit from the attention and supply shortage. But scientists and investors say that lower efficacy plus side effects could continue to hold the treatments back.

Britain plans to launch a pilot programme exploring how new weekly weight-loss shots such as Novo Nordisk's Wegovy can be given to obese patients by general practitioners even as the drug's market launch remains unclear. The government's announcement on the £40 million pilot programme comes after drug cost-effectiveness watchdog NICE in March recommended the use of Wegovy in adults with at least one weight-related condition and a body mass index of 35, but only within the NHS specialist weight management scheme. The timing of Wegovy's launch in Britain - which would be only the fourth country to use it - is uncertain, however, after Novo last month rationed starter doses to secure supply to U.S. patients already on the regimen, after it was overwhelmed by demand there. British Prime Minister Rishi Sunak said on Wednesday (May 7) the pilot and fighting obesity-related diseases could reduce pressure on hospitals. It would also support "people to live healthier and longer lives, and helping to deliver on my priority to cut NHS waiting lists". The NHS endured a tough winter in England in particular, with waiting lists hitting record highs and staff striking for higher pay amid double-digit inflation.

Denmark's Zealand Pharma and Boehringer Ingelheim said their experimental obesity treatment achieved up to 14.9% weight loss in a mid-stage trial, lining up a potential contestant in the booming obesity drug market. In a statement on Wednesday (May 10), the partners said that the Phase II dose-finding trial met its primary endpoint of weight loss after 46 weeks. Paola Casarosa, head of therapeutic areas at Germany's Boehringer Ingelheim told Reuters the partners are in discussion with regulators about the design of a planned follow-up trial in the third and last phase of testing. The enormous demand for weight-loss treatments such as Novo Nordisk's Wegovy, or potentially Eli Lilly's Mounjaro, could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said. Lilly said about a year ago that Mounjaro was shown to reduce up to 22.5% in weight after 72 weeks of treatment in a much larger late-stage trial.

An average American diet is high in high-fructose corn syrup. Check out the possible health effects of high fructose corn syrup and obesity as experts share their thoughts here.

Excessive amount of body fat is medically known as obesity or overweight and this condition is contribute many health issues such as uncontrolled diabetes, high blood pressure, heart diseases etc. Here are the tips that will help you to shed extra body fat naturally and prevent the risk of this chronicle disease.

Are you worried you are getting heavier day by day? Well, it might be because of those fries you are addicted to. Deep fried foods are rich in trans fats which are directly related to obesity and heart failure. Trans fats build up the blood vessels, hindering the smooth flow of blood through them.

Want to know about metabolism and weight loss and how it affects your health and lifestyle. Visit Metabolism.com to find all the trustworthy and latest information related to its causes, symptoms, treatment, and more.

If you're a teenager who has excessive weight, you may raise your risk for certain health problems including diabetes, sleep apnea, and even cancer. Our obese teenager lose weight treatment program will help you overcome obesity while maintaining a healthier lifestyle.

There are many ways to treat a slow metabolism. A doctor may prescribe medication to help increase the metabolism. Some people may need to change their diet or exercise regimen to lose weight. Slow metabolism is an underlying cause of obesity that prevents the body from losing weight. Metabolism is the process by which a body breaks down food to make energy. A slow metabolism means that a person may not be burning as much fat and calories as others might. nIn order to increase a slow metabolism, a person may have to exercise more or eat fewer calories in a day.

Wegovy maker Novo Nordisk said on Tuesday (Aug 8) a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit, boosting the Danish company's hopes of moving beyond its image as a lifestyle drug. The increasingly popular Wegovy has transformed the weight-loss market since its U.S. launch in June 2021, capturing the attention of patients, investors and celebrities worldwide. Novo's news lifted shares in Europe's second-most valuable listed company after LVMH by more than 17 per cent to record highs. They have now surged almost 165 per cent over the past two years. The results of the late-stage trial may help persuade insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy, which is $1,300 a month in the United States, for a wider range of patients. U.S. law classifies weight-loss treatments as lifestyle drugs and bars the Medicare health plan for older Americans from covering them and experts said the new data could lead the U.S. government to reassess that.

Capitalising on strong demand for its obesity therapies, Novo Nordisk's growing appetite for deals has fuelled a bet on a U.S. gene-editing company called Life Edit Therapeutics. The Danish drugmaker's collaboration with Durham, North Carolina-based Life Edit Therapeutics - owned by ElevateBio, a cell and gene therapy company in Waltham - is focused on up to seven programs for rare genetic disorders as well as cardiometabolic diseases. At the heart of the tie-up is Life Edit's technology, called base editing, which is designed to make precise changes to the human genome by tweaking one base - or letter - into a different one without affecting other letters. Single-letter mistakes, called point mutations, can give rise to genetic diseases.